Miranda Cole

Partner
Norton Rose Fulbright LLP

Brussels T:+32 (2) 2376198

London T:+44 20 7283 6000

Brussels T:+32 (2) 2376198

London T:+44 20 7283 6000

Miranda Cole

Miranda Cole is an antitrust and competition lawyer working from our Brussels and London offices. She has a broad competition practice focussed on the technology, life sciences and healthcare, transport, and energy, infrastructure and resources sectors.

With more than 20 years' experience, Miranda is regarded as a key adviser to life sciences and technology companies globally.

Miranda has extensive experience advising clients to address increasing regulatory scrutiny from governments and competition authorities. She advises on merger control, actions under Articles 101 and 102 TFEU, abuse of dominance, anticompetitive agreements, and compliance and advisory work, as well as actions before the European courts in Luxembourg.

Miranda is also heavily involved in supporting clients in aligning their competition policy engagement in response to a variety of new regulatory frameworks.

Prior to joining the firm, Miranda was a senior partner in a multinational law firm in Brussels.

Professional experience

Expand all

Education

LL.M (Distinction), University of London, 1997
LL.B (University Medal), The University of Queensland, 1993
B.A. (First class), The University of Queensland, 1991

Admissions

Registered at the Brussels Bar
Solicitor of the Senior Courts of England and Wales
Federal Court and High Court of Australia
Law Society of Ireland

Representative experience

Advising:

Facebook - in its acquisitions of WhatsApp and Instagram*
Microsoft - in connection with its acquisition of ZeniMax*
Renesas - in its acquisition of Dialog*
The Walt Disney Group - in connection with its acquisition of 21st Century Fox*
Central European Media Enterprises Ltd (CME) - on the sale of broadcast operations to Slovenia Broadband S.à r.l and other broadcast operations to the PPF Group*
AstraZeneca - in various acquisitions, including of Almirall's respiratory portfolio, certain diabetes products from BMS, Takeda's respiratory business, Ardea Biosciences, and certain products divested in connection with AbbVie/Allergan*
MSD - in its acquisitions of Acceleron Pharma, Themis Bioscience, and Antelliq*
Illumina - in connection with its attempted acquisition of Pacific Biosciences*
UCB - on its acquisitions of Zogenix, and the rights to Nayzilam*
Eaton - in its acquisition of Cobham Mission Systems*
Technology sector clients - responding to the European Commission's Internet of Things investigation and related issues, including voice assistants and app stores*
Technology sector clients - responding to the CMA's mobile ecosystem market study and related issues, including app stores*
Entities - in connection with the investigations of the activities of Amadeus and Sabre in relation to the supply of CRS and PSS services, and the revision of the EU CRS Code of Conduct*
A Dutch pharmaceutical Contract Manufacturer in connection with a CMA investigation of certain agreements.*

*Prior to joining the firm.

Rankings and recognitions

Leading individual, EU and Competition, The Legal 500 UK, 2022
Notable practitioner, Competition/European Law (Belgium), Chambers Global, 2013-2021
Women in Antitrust, Global Competition Review, 2021; 2016
Notable practitioner, Competition/European Law, Chambers Europe, 2013-2019
"really excellent" (2021)
"really very knowledgeable" (2020)
"first-hand experience... a solid understanding of her clients' business and always puts her clients first" (2019)
"pragmatism and ability to put the risks into proportion and help us make judgement calls" (2018)
Shortlisted for Europe Women in Business Law Awards for Competition and Antitrust, Euromoney Legal Media Group, 2014-2018; 2021